Jazz Pharmaceuticals Shows Xywav Low-Sodium Regimen Cuts Cardiometabolic Risks in 13,000 Patients
JAZZ•Jazz Pharmaceuticals presented 11 late-breaking SLEEP 2026 abstracts detailing Xywav’s individualized dosing regimens reaching stable dose in ~42 days (range 12–67) and real-world data from 13,000 patients. Retrospective EHR analysis showed Xywav initiation lowered non-HDL cholesterol, triglycerides and systolic blood pressure, highlighting cardiometabolic benefit of its low-sodium formulation.
1. Conference Presentations Overview
Jazz Pharmaceuticals featured 11 late-breaking presentations at SLEEP 2026 highlighting research on Xywav’s effects in narcolepsy and idiopathic hypersomnia. The data focused on treatment outcomes, sodium reduction and patient-reported symptom improvements across diverse dosing regimens.
2. Individualized Dosing Findings
Individualized dosing regimens from the Phase 4 DUET study showed patients reached stable Xywav doses in mean 42.1 days (range 14–62) for idiopathic hypersomnia and 41.8 days (range 12–67) for narcolepsy. The Xywav REMS program analysis of over 13,000 patients confirmed feasibility of personalized dosing in real-world settings.
3. Cardiometabolic Benefit Evidence
Retrospective EHR analysis demonstrated that initiation of low-sodium Xywav was associated with declines in non-HDL cholesterol, triglycerides and office systolic blood pressure, alongside increased HDL levels in high-sodium oxybate switchers. These findings suggest cardiometabolic risk mitigation benefits tied to Xywav’s low-sodium formulation.
